The Bulletin
The Times


.

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

  • Written by The Bulletin

New commercialisation agreement builds on existing partnership with Zuellig Pharma

SINGAPORE - Media OutReach Newswire - 16 January 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV® Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.

Read more: Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese...

hacklink hack forum hacklink film izle hacklink online casinos australiaonwinonline casino australiasahabetskorbetroyalbet girişjojobettelegram ifşadeneme bonusubandar bolanon gamstop casinosonline casinosonline casinovedonlyöntimaailmaonline casinos australiaaustralian online casinosroyal reelsroyal reelsroyal reels casino australiaroyalreels.pokerroyal reels casinocasibomnakitbahisjojobetjojobetthe pokies net onlinejojobet